2026-04-17T00:56:52Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/135012025-09-30T02:08:53Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Dettmer, Matthias
author
Führer-Sakel, Dagmar
author
Hadoux, Julien
author
Ryska, Ales
author
Capdevila Castillon, Jaume
author
ELISEI, ROSSELLA
2025-09-30T02:08:53Z
2025-09-30T02:08:53Z
2025-08-07T06:54:29Z2025-08-07T06:54:29Z2025-08
http://hdl.handle.net/11351/13501
Biomarkers; Molecular testing; Thyroid cancerBiomarcadores; Pruebas moleculares; Cáncer de tiroidesBiomarcadors; Proves moleculars; Càncer de tiroidesAs new precision oncology therapies become available in the thyroid cancer (TC) treatment landscape, appropriate and timely biomarker testing is crucial for treatment selection and requires a multidisciplinary approach. Recently published European guidelines on advanced/metastatic TC management include a special focus on biomarker testing. However, to date, there remains a need for comprehensive European guidance for standardized molecular testing strategies in TC that encompass a broad set of targetable or potentially targetable alterations, timing of testing, and patients to be tested. This expert opinion article outlines consensus testing algorithms for differentiated TC, medullary TC, and anaplastic TC from a team of endocrinologists, oncologists, molecular biologists, and pathologists to provide standardized recommendations for physicians involved in treating patients with advanced TC. In the differentiated TC algorithm, patients recommended for comprehensive testing by DNA and RNA next-generation sequencing (NGS) include those whose disease has progressed on or is resistant to radioactive iodine treatment. The medullary TC algorithm recommends RET germline testing for all patients at diagnosis. For patients exhibiting high-risk clinical or pathological features and those whose disease progresses, somatic RET testing with NGS should be discussed and conducted before considering systemic treatment. As anaplastic TC is a highly aggressive disease, molecular reflex testing for BRAF mutations is recommended for all patients at diagnosis, followed by DNA and RNA NGS for those who test BRAF negative. The article also provides consensus recommendations on the use of tumor tissue for testing and on centralization of molecular testing involving multidisciplinary tumor boards.Funding for the development of this manuscript was provided by Eli Lilly and Company.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Tiroide - Càncer - Diagnòstic
Marcadors tumorals
Decisió, Presa de
CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms
Other subheadings::Other subheadings::/diagnosis
PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides
Otros calificadores::Otros calificadores::/diagnóstico
PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::psicología social::procesos de grupo::consenso
Molecular predictive biomarker testing in advanced thyroid cancer – a European consensus
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion